Page 18 - Pharmaceutical

Piramal Enterprises buys US-based Ash Stevens to tap high potency APIs market

The company will buy the US-based contract development and manufacturing organisation (CDMO) for a total consideration of $ 42.95 million (about Rs 286 crores)

Lonza buys InterHealth Nutraceuticals for $ 300 million

Acquisition will strengthen Lonza's specialty nutritional ingredients portfolio

US FDA issues establishment inspection report for Natco's Kothur facility

The Kothur facility predominantly caters to regulated international markets, including USA

Cipla names Umang Vohra as MD & Global CEO

The current incumbent, Subhanu Saxena will step down from his position on August 31, 2016. The company also announced that Samina Vaziralli will become executive vice-chairman

Lupin receives US FDA for electrolyte replenisher

The approved product, potassium chloride extended-release tablet, is a generic version of Upsher-Smith Labs' Klor-Con tablet

Sun Pharma extends patient support program for cancer drug in US

Started as part of the imatinib mesylate launch in February 2016, the program is aimed at delivering greater access to the drug to patients

Natco Pharma receives US FDA approval for generic Tamiflu capsules

Tamiflu oral capsules (Roche's trade name for oseltamivir phosphate) had US sales of about $ 403 million for twelve months ending December 2015, according to IMS Health

Dr Reddy's completes acquisition of product portfolio from Teva

The combined sales of the branded versions of these products in the US is about $ 3.5 billion MAT for the most recent twelve months ending in June 2016, according to IMS Health

Sun Pharma receives US FDA nod for diabetes drug metformin ER tablets

These tablets, which are generic versions of Glumetza, have annual sales of approximately $ 1.2 billion in the US, according to IMS Health

Lupin acquires 21 branded products from Japan's Shionogi for $ 150 mn

These 21 products, covering therapy areas such as central nervous system (CNS), oncology, cardiovascular and anti-infectives, had sales of Yen 9.4 bn ($ 90 million) collectively

Suven receives patents for CNS drug in Macau and New Zealand

These patents are valid through 2032

Borosil Glass buys 60% stake in glass packaging company Klasspack

With this, Borosil has entered into primary pharma glass packaging business

China's Fosun Pharma acquires 86% stake in Gland Pharma for $ 1.26 bn

Acquisition will help Fosun Pharma to strengthen its presence in the global injectables market - one of the fastest growing segment within pharma industry

Amend Drugs and Cosmetics Act to promote e-pharmacy in India

While e-pharmacy offers convenience to people, there are concerns with respect to legitimacy of e-pharmacies, patients' safety and privacy, adverse effect on retailers business, etc

Sun Pharma signs licensing pact with Spain's Almirall for tildrakizumab in Europe

As per the agreement, which will fetch Sun Pharma $ 50 mn as an initial upfront payment, Almirall will lead the marketing effort of tildrakizumab for treatment of psoriasis in Europe

RPG Life Sciences buys Sun Pharma's 7 brands for Rs 41 crore

Divested products include brands used for treatment of respiratory-track infections, urological disorders, cardiovascular diseases, etc

Vivimed arm Klar Sehen divests certain products to Ordain Healthcare for Rs 73 cr

The move is part of Vivimed's strategy to exit from the branded formulations in ophthalmology and to focus on CMO and US generic business

European drug regulator suspends medicines tested at Semler Research

European Medicines Agency has cited flaws in bioequivalence studies, which are required for the approval of generics, conducted at the Bangalore-based CRO as the reasons for suspension

US FDA grants approval for Glenmark's skin ointment

The approved product, triamcinolone acetonide ointment (0.5 percent), achieved annual sales of about $ 4.4 million in the US, according to IMS Health

European drug regulator accepts Mylan-Biocon application for biosimilar Pegfilgrastim

The proposed biosimilar Pegfilgrastim, used to treat cancer, is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace